Literature DB >> 12360601

[Use of thymodepressin for treating autoimmune cytopenia].

Iu E Vinogradova, I A Zamulaeva, V V Pavlov, E I Selivanova, V I Deĭgin, S G Smirnova, N V Orlova, A S Saenko.   

Abstract

AIM: To study influence of thymodepressin on the course of autoimmune cytopenia.
MATERIAL AND METHODS: Thymodepressin is a new synthetic hemoregulatory dipeptide (gamma-D-Glu-D-Trp). It was used for the treatment of 22 patients with autoimmune cytopenia.
RESULTS: Hemoglobin levels were elevated in autoimmune hemolytic anemia and platelet levels were high in idiopathic thrombocytopenic purpura. A thymodepressin course resulted in a fall of total lymphocyte count and activated CD3+CD69+ lymphocytes.
CONCLUSION: The above results, safety, absence of toxicity and allergenicity, parenteral and intranasal useability open perspectives for further studies of therapeutic action of thymodepressin as an immunodepressant in autoimmune processes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12360601

Source DB:  PubMed          Journal:  Ter Arkh        ISSN: 0040-3660            Impact factor:   0.467


  1 in total

1.  Thymodepressin-Unforeseen Immunosuppressor.

Authors:  Vladislav I Deigin; Julia E Vinogradova; Dmitry L Vinogradov; Marina S Krasilshchikova; Vadim T Ivanov
Journal:  Molecules       Date:  2021-10-29       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.